Close Menu

NEW YORK – Investigators from the Targeted Agent and Profiling Utilization Registry (TAPUR) study have shown that palbociclib (Pfizer's Ibrance) shows activity in some non-small cell lung cancer patients with alterations in CDKN2A.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.